Synlogic, Inc. (SYBX)

Market Cap	16.61M
Revenue (ttm)	2.78M
Net Income (ttm)	-37.18M
Shares Out	11.70M
EPS (ttm)	-3.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,343
Open	1.395
Previous Close	1.420
Day's Range	1.374 - 1.420
52-Week Range	1.220 - 5.120
Beta	0.81
Analysts	Hold
Price Target	1.00 (-29.58%)
Earnings Date	Nov 12, 2024

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat hom...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Antoine Awad
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: SYBX
• Website: https://www.synlogictx.com

Financial Performance

In 2023, Synlogic's revenue was $3.37 million, an increase of 185.68% compared to the previous year's $1.18 million. Losses were -$57.28 million, -13.40% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for SYBX stock is "Hold." The 12-month stock price forecast is $1.0, which is a decrease of -29.58% from the latest price.

Price Target

$1.0

(-29.58% downside)

Analyst Consensus: Hold